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Abstract
Background: The global population is ageing quickly and our understanding of age-related changes in the
immune system suggest that the elderly will have less immunological protection from active tuberculosis (TB).
Discussion: Ongoing global surveillance of TB notifications shows increasing age of patients with active TB. This
effect of age is compounded by changes to clinical manifestations of disease, confounding of diagnostic tests and
increased rates of adverse reactions to antimicrobial treatment of TB. Future epidemiological surveillance,
development of diagnostic tests and trials of treatment shortening should all include a focus on ageing people.
Summary: More detailed surveillance of TB notifications in elderly people should be undertaken and carefully
evaluated. Risk stratification will help target care for those in greatest need, particularly those with comorbidities or
on immunosuppressive therapies. Novel diagnostics and treatment regimes should be designed specifically to be
used in this cohort.
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Background
Ageing of global populations
The global population is ageing due to longer life ex-
pectancy and lower rates of child birth. By 2035, it is
projected that those aged >65 years will constitute 23 %
of the total UK population [1]. Worldwide, the number
of people > 60 years is expected to increase by more than
double, from 841 million people in 2013 to more than
two billion people in 2050 [2]. It is projected that in
2047, older persons will exceed the number of children
for the first time [2]. Currently most older people live in
the developed world, but the older population is also
growing rapidly in less developed regions such that pro-
jections for 2050 predict nearly 80 % of the world’s older
population will be living in less developed countries [2].
Effects of age on immune protection against TB
Elderly people have an increased susceptibility to infec-
tious diseases, particularly of the respiratory tract [3],
and suffer greater morbidity and mortality compared to
younger individuals [4]. Ageing has significant effects on
both the innate and adaptive immune system [5–7],
which may contribute to the increased risk of infection.
Immune protection against tuberculosis (TB) infection
is primarily achieved by cell mediated immunity, through
the coordinated action of phagocytic cells and adaptive
immune T cell responses that serve to kill or contain the
bacteria. In this context, macrophages represent the pre-
dominant phagocytic cells [8], CD4 T helper 1 cells are
thought to enhance intracellular killing of bacteria
through the action of interferon (IFN)γ and CD8 T cells
may contribute to killing of infected macrophages by pro-
duction of cell membrane porins such as granzyme and
perforin [9].
Reduced T cell output by the thymus, T cell immune
senescence, defined by reduced capacity for cell prolifera-
tion, and immune exhaustion, defined by reduced capacity
to produce cytokines and other effector molecules are the
most consistent reported effects of ageing on the immune
system [10, 11]. In keeping with these data, ex vivo stimu-
lation of peripheral blood mononuclear cells from elderly
people with Mycobacterium tuberculosis (Mtb) antigens
generates lower IFNγ responses, than in younger people
[12], and older mice show increased susceptibility to Mtb
infection, associated with impaired CD4 T cell-mediated
immunity [13, 14]. However, others report exaggerated
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CD8 T cell responses in older mice which mediate a de-
gree of increased host resistance to TB [15–17].
Age-related changes in the phenotype and function of
macrophages are also reported, which might be expected
to compromise their role in protection against TB.
These include reduced expression of innate immune re-
ceptors, reduced production of tumour necrosis factor
(TNF) and reduced phagocytosis [18]. Clear evidence for
how these may impact the host-pathogen interactions
between macrophages and Mtb is lacking. In one report,
monocytes from older humans supported higher rates of
bacterial growth [19] but others found no difference in
cellular cytokine responses or bacterial growth in mouse
macrophages from young and old mice [20].
The importance of well-calibrated mechanisms for
regulation of inflammation to avoid or minimise the
immunopathogenesis of TB are also increasingly recog-
nised [21–23]. Persistently raised levels of proinflamma-
tory cytokines are evident in older people [24, 25] and in
pulmonary macrophages of older mice [26]. These data
invite speculation that inflammage-ing may contribute
to increased immunopathogenesis of TB and therefore
more disease in the elderly.
Discussion
Evidence for the impact of ageing on TB
Currently the highest TB notification rates globally
occur amongst 45–55 year olds, but in the Western
Pacific Region, Eastern Mediterranean and South East
Asia TB notifications are increasingly evident in older
people, peaking amongst those aged ≥65 years old [27].
Similar observations have been reported in a recent re-
view of all national TB prevalence studies in Asia which
showed progressively increased TB prevalence rates
amongst people over the age of 65 years [28], and this is
echoed in reports from the Americas which also de-
scribed the disease burden increasing amongst older
adults in Central and South America [29] and North
America [30].
Currently in the United Kingdom (UK), the highest in-
cidence of TB is amongst 15–44 year olds, representing
nearly 60 % of all cases and those over the age of 65 years
only accounted for 14 % [31]. Interestingly, the majority
of the younger cases are in non-UK born individuals,
most likely due to high immigration rates in younger
people from TB endemic areas, confounding our percep-
tion of TB risk in the elderly population. Even in the
UK, there is a comparatively high incidence of TB in UK
born individuals, greater than 75 years old [31]. Birth co-
hort effects, such as higher childhood or early adulthood
TB transmission rates amongst the current elderly may
partly explain these observations [32] as it is has long been
presumed that active TB in the elderly arises from reacti-
vation of LTBI as protective immunity wanes [33–35].
However the emerging general consensus is that LTBI is
most likely to reactivate within 18 months of infection,
and disease resulting from reactivation more than 10 years
after infection may be rare [36] and that most active dis-
ease represents relatively recent transmission events.
Whether these observations are equally true in young and
old people alike is not known and merits further investiga-
tion, particularly given the age-related immune changes
and co-morbidities in older people, which may increase
the risk of reactivation disease.
Effects of age on clinical presentation of TB
It has been argued that active TB infection in the elderly
is “a different disease” than that occurring in younger
people, due to the disparity in clinical presentation and
laboratory tests [34]. Although pulmonary TB is the
most common site of infection in elderly people, occur-
ring in approximately 75 % of cases [37], many older pa-
tients with active TB may not exhibit the classic clinical
features such as cough, hemoptysis, fever, night sweats
and weight loss. Dyspnoea is more common and haem-
optysis less common in the elderly [34, 38–40]. There
may be very few symptoms, or the symptoms can mimic
age-related illnesses such as reduced functional capacity,
chronic fatigue, cognitive impairment, anorexia or
pyrexia of unknown origin. An accurate history may be
difficult to obtain due to poor memory, impaired hear-
ing, sight or speech.
Extrapulmonary TB is more common with advancing
age, and presentations may include TB meningitis, renal
or bone and joint infection (particularly involving the
thoracolumbar spine and large joints) [38, 41, 42]. Pre-
sentations of back and joint pain are sometimes dis-
missed as diseases of the elderly, such as degenerative
arthritis or osteoporotic compression fractures [43], but
associated constitutional symptoms (low grade fever,
weight loss, fatigue and anorexia) can lead to the correct
diagnosis.
The impact of age on diagnosis
Diagnosing TB can be difficult in all age groups and is
often dependent on identifying those with compatible la-
boratory and radiological assessments, particularly when
a microbiological diagnosis may be out of reach. By
comparison to the young, elderly people with TB show
higher frequencies of abnormal liver enzymes, hypoalbu-
minaemia, hyponatraemia and hypokalaemia, and about
two-thirds of elderly patients with active TB exhibit a
normocytic normochromic anaemia [34]. Less pulmon-
ary cavitation is seen on plain radiographs [37], and
fewer nodules, masses and cavities on chest computed
tomography have been reported in the elderly [40], albeit
not always consistently [39]. Rather than isolated apical
shadowing, radiographs more often show mid zone and
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basal shadowing often accompanied by pleural effusions
[34]. Moreover, mass-like lesions or nodules due to TB
in the elderly can often be difficult to distinguish from
malignant disease or more common bacterial pneumo-
nias [35].
The age-related changes to the immune system de-
scribed above may also compromise immunological tests
for evidence of past exposure to TB, such as the tubercu-
lin skin test (TST) or peripheral blood IFNγ release assays
(IGRA) such as the T-SPOT.TB and QuantiFERON-TB
Gold In-Tube. Lower rates of positive TST have been de-
scribed in elderly populations, compared to younger
people [37, 44], including a study of UK nursing home
residents that showed a lower rate of TST positivity (3 %)
in those aged over 90 years, compared to those under
70 years old (15 %) [45]. However other studies have not
shown any age-related difference in TST positivity rate
[40]. Studies of repeated TST in the elderly typically show
reduced TST reactivity [46, 47], usually interpreted as evi-
dence for waning immunity. Therefore the use of a
boosted (two-step) TST is advocated in the elderly to im-
prove sensitivity, though this is not predictive of active TB
disease [48].
Data on the use of peripheral blood IGRAs in the elderly
are limited. Some suggest indeterminate results may be
more likely to occur [49, 50] and other reports show no
effect of age [47]. However, discordance between TST and
IGRA is more likely to occur in the elderly [47, 51].
There is also controversy in the literature about
whether microbiological diagnosis of TB is affected by
age, with reports of lower rates in the elderly [52, 53],
no difference between groups [54] or higher rates of
smear positive sputum in the elderly [40]. There are cur-
rently no published reports of the impact of age on Gen-
eXpert molecular diagnostics for TB.
Age-related effects on anti-tuberculous treatment
Elderly people are more likely to develop adverse drug
reactions from polypharmacy, existing co-morbidities
and age-related physiological changes. Hepatotoxicity is
a common adverse effect as a result of treatment with
isoniazid, rifampicin and pyrazinamide, ranging from
mild reversible abnormalities of transaminases to ful-
minant liver failure, and hepatotoxicity from anti-
tuberculous drugs rises significantly with increasing age
[38, 55, 56]. TB drug related hepatotoxicity in those
older than 65 years incurs an odds ratio of 1.71 (CI 95 %
1.24–2.35) [56], although cessation of isoniazid therapy
due to suspected hepatotoxicity is not associated with
increasing age [57].
Although less common, acute kidney injury is also
seen following anti-tuberculous therapy, particularly
with rifampicin [58, 59]. This is more likely to occur
with increasing age, and with co-morbidities of diabetes
mellitus and chronic kidney disease [59].
In addition to increased adverse drug reactions, visual
impairment, poor memory and reduced mobility may
cause poor adherence to the drug regimen [35].
Comorbidities and therapies in an ageing population
associated with increased risk of TB
Several co-morbidities that are prevalent in ageing popu-
lations may further increase the risk of developing active
TB disease. Diabetes mellitus increases the risk of active
TB by approximately three fold (relative risk 3.11, 95 %
CI: 2.27–4.26), in all age groups but may contribute to
age related TB as the prevalence of diabetes increases
with age [60]. Similarly in chronic obstructive pulmonary
disease (COPD), incidence and severity increases with
age, and it is also associated with increased rates of
active TB, albeit the effect also seems to be independent
of age [61].
Furthermore elderly patients are more frequently
treated with medication that may suppress protective
immunity. The most common example of this is cortico-
steroids, especially in those with COPD. Both regular
inhalers and short courses of high dose corticosteroids
during exacerbations are associated with an increased risk
of TB in younger and older patients, in a dose-dependent
fashion [62–64]. Corticosteroid use (oral prednisolone >
7.5 mg daily) in other diseases is also an independent risk
factor for active TB infection [65, 66]. In a study of older
people with rheumatic conditions, those on immunosup-
pressive medication were at an increased risk of mycobac-
terial infection [67]. Amongst these immunosuppressive
therapies, anti-TNF therapy particularly increases the risk
of active TB [67–69].
Conclusions
Given the global ageing population and increasing inci-
dence of active TB in the elderly, it would be prudent to
undertake more detailed surveillance of this cohort. Of
note there are no data that assess the differential effects of
age on transmission of infection, likelihood of developing
latent TB or progressing to active disease. Careful evalu-
ation of de novo infection and reactivation of LTBI may
help to risk stratify patients and target care to those at the
highest risk of developing active TB, particularly to assess
the role of comorbidities and immunosuppressive treat-
ments. TB in the elderly also generates substantial
diagnostic and treatment challenges. The performance of
established and novel diagnostics, and new treatment
regimens aiming to reduce the duration of treatment in
TB should all be specifically evaluated in elderly popula-
tions, which have generally been avoided in the past be-
cause of practical difficulties in their inclusion and their
comorbidities.
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